China's ** newspaper published an article "Coal is completely on fire!".Can you still get on the bus?The blockbuster interpretation is coming", its China Lian** Chen Xinyu said, "Sectors with strong beta attributes, the index ** is a very suitable investment tool, such as coal, steel, securities and military industry." For the pharmaceutical, chemical and non-ferrous metals and other sub-sectors are particularly numerous, the logic and rhythm of the rise and fall of the sub-industries are not completely consistent, at this time, either choose index products that are more sub-sub-sectors, or choose the alpha ability of active managers
I'll take advantage of the weekend to pull the data of the pharmaceutical ** again.
1. Ranking of pharmaceutical performance in the past three years
There are 433 ** indexes in the whole market**, the first place in the performance benchmark, with "medicine" or "medicine" in the name, of which 172 ** meet the three-year performance, and 117 ** are left for multiple shares only to retain class A or RMB shares.
117** are ranked from high to low according to their performance in the past three years, which also shows the interval annualized return, interval maximum drawdown, interval Sharpe ratio, interval karma ratio.
Data**: Dongcai Choice data, as of January 5, 2024, past performance is not indicative of future trends.
In the past three years, Fan Jie, who has been ranked first and last in Qianhai Open Source, has won the first place in Qianhai Open Source Traditional Chinese Medicine**a (005505), with an interval return of 4044%；The 117th place is Qianhai Open Source Medical Health A (005453) managed by her, with an interval return of -6388%, the difference between the first and last performance is more than 100%. Therefore, the sub-sectors of medicine are indeed quite different.
In the past three years, the second place is Li Mingwei's Bank of China ** Health Industry Mixed (002938), with a range return of 3230%, but he took office later, on February 22, 2023. It is speculated that the **management process is also involved in the ** of traditional Chinese medicine, and the length of the article is not expanded.
The third place in the past three years is a QDII passive exponential **:GF Global Healthcare Index RMB (QDII) A (000369)., range return 2926%, the biggest highlight is that the maximum drawdown in the last three years is only -1047%, which is the best drawdown data among 117**. This ** tracks the S&P Global 1200 Healthcare Index using a full replication method.
The fourth place in the last three years is:Traditional Chinese medicine **LOF (501011)., range return 2487%, tracking the CSI Chinese Medicine Index, the constituent stocks of the index are Pien Tze Huang, Yunnan Baiyao, Tong Ren Tang, Dong'e Ejiao, Baiyunshan, and China Resources.
Three. 9. Yiling Pharmaceutical, Taiji Group, Tasly, Jilin Aodong.
In the past three years, it has ranked fifthS&P Healthcare LOF (161126)., range return 2094%, the ** scale is unfortunately only 04.3 billion yuan. The difference between the S&P 500 Healthcare Equal Weight Index tracked by this ** and the above-mentioned GF ** is that GF is "global".
In the past three years, only these 5 have returned more than 20% in the range**.
It was followed by Wan Minyuan, Gai Junlong, and Xiao Shiyuan.
2. **The company's holdings rank among the top 50
As I just said, the index that ranks first in the performance benchmark of the whole market, with "medicine" or "medicine" in its name, has 433**.
As of September 30, 2023, the top 50 companies held by ** companies are displayed as follows:There are two ** companies that hold more than 40 million yuan, namely Guotai Junan Innovative Pharmaceutical Mixed Initiation and China Universal Pharmaceutical and Health Care Mixed.
Data**: Dongcai Choice data, as of January 5, 2024.
There is only 1 company holding more than 30 million yuan-40 million yuan**, which is Tianhong Pharmaceutical Innovation A, and 3 companies holding more than 20 million yuan-30 million yuan, respectively, China Universal Healthy Life holds a hybrid A for one year, Hong Kong Stock Connect Pharmaceutical ETF, China Post Pharmaceutical and Health Flexible Allocation Mix, and other specific data can be seen**.
3. The top 50 institutions in terms of amount of holdings
As of June 30, 2023, the top 50 holdings of institutions are shown as follows: the top rankings are all passive index**. If you look at the active type, Yang Zhenxiao, Wan Minyuan, Chi Chensen, etc. are relatively recognized by institutions. (As of June 30, 2023).
Data**: Dongcai Choice data, as of January 5, 2024.
Fourth, the top 50 internal employees hold the amount
As of June 30, 2023, the top 50 internal employees are shown as follows: The top ones are all active**, of which Jiang Qi was held by internal employees up to 1770040,000 yuan, which is held by internal employees more than Yang Zhenxiao, Wang Zhengjiao, Chi Chensen, etc.
Data**: Dongcai Choice data, as of January 5, 2024.
5. What is the current valuation of the 28 pharmaceutical industry indexes?
433**, of which 141 are passive exponential** and 7 are enhanced exponential**. 28 billion-dollar indices were involved:
Data**: Dongcai choice data.
If each index retains only the largest tracker**, the 28** are shown below:It can be seen that the relatively mainstream ones are the CSI Medical Index, Pharmaceutical Index**, Biomedical Index** and so on.
Data**: Dongcai Choice data, as of January 5, 2024.
The 28 indices are ranked according to the average return (annualized) data since the base period from high to low, the top ones are Pharmaceutical 100, CS Pharmaceutical TI, Quanzhi Medicine, Guozheng Medicine, Pharmaceutical Biology and so on.
Data**: Dongcai Choice data, as of January 5, 2024, past performance is not indicative of future trends.
The P/E ratio, P/E valuation percentile, P/B ratio, P/B ratio, P/B ratio valuation percentile, and **2024 P/E ratio data are shown below. Take the first place Pharmaceutical 100 Index as an example, the current price-earnings ratio is 2824 times, at the valuation percentile of 8 since the base period75%, P/B ratio of 330 times, at the valuation percentile of 2 since the base period79%, which is basically underestimated from the data.
Data**: Dongcai Choice data, as of January 5, 2024, past performance is not indicative of future trends.
Do you have any of the above 28 indexes?Or do you buy the active **?
My article is basically ** combing notes, the amount of information is still relatively large, thank you for your patience to read, all content is personal research, does not constitute investment advice, please pay more attention to objective data.
Risk Disclosure:The relevant views quoted are from relevant institutions or public channels, and I do not make any guarantee for the accuracy and completeness of the views, and investors operate accordingly at their own risk. The market is risky, regular investment is risky, and investment needs to be cautious. The above content is for reference only, the article involves **, does not constitute **recommendation and investment advice, **market volatility, please operate cautiously before purchasing. China's first operation time is short, and it cannot reflect all stages of development. The Manager does not guarantee the profit and minimum returns, and the other performance of the Manager does not constitute a guarantee of the performance of the Administrator. **Past performance and its net worth are not indicative of future performance, and the full results can be found on the product details page. **The product has the risk of income fluctuation, investors should agree with the principle of "buyer's responsibility" when making ** investment decisions, and after making ** investment decisions, the investment risks and losses caused by the changes in **operating conditions and **net value shall be borne by ** investors. Investors should carefully read the "** Contract", "Prospectus" and other ** legal documents to confirm that they know and understand the product features and related risks, and have the corresponding risk tolerance. The market is risky and investors should be cautious.